[1] |
Coyne K S, Margolis M K, Kopp Z S, et al. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS study[J]. Urology, 2012, 79(1):95-101.
doi: 10.1016/j.urology.2011.09.010
|
[2] |
王驭良, 许克新, 胡浩, 等. 北京地区成年女性膀胱过度活动症流行病学调查及对患者生活质量的影响[J]. 中华泌尿外科杂志, 2010, 31(8):550-554.
|
[3] |
Hsiao S M, Lin H H. Medical treatment of female overactive bladder syndrome and treatment-related effects[J]. J Formos Med Assoc, 2018, 117(10):871-878.
doi: 10.1016/j.jfma.2018.01.011
|
[4] |
Malde S, Fry C, Schurch B, et al. What is the exact working mechanism of Botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity?[J]. Neurourol Urodyn, 2018, 37(S4):108-116.
|
[5] |
De Wachter S, Benson K D, Dmochowski R R, et al. 6-month results of selective bladder denervation in women with refractory overactive bladder[J]. J Urol, 2018, 5347(18):43909-43912.
|
[6] |
De Groat W C. A neurologic basis for the overactive bladder[J]. Urology, 1997, 50(6):36-52.
doi: 10.1016/S0090-4295(97)00587-6
|
[7] |
Haferkamp A, Dorsam J, Elbadawi A. Ultrastructural diagnosis of neuropathic detrusor overactivity: validation of a common myogenic mechanism[J]. Adv Exp Med Biol, 2003, 539:281-291.
pmid: 15088911
|
[8] |
Birder L, Andersson K E. Urothelial signaling[J]. Physiol Reviews, 2013, 93(2):653-680.
doi: 10.1152/physrev.00030.2012
|
[9] |
Dagdeviren H, Cengiz H. Association between metabolic syndrome and serum nerve growth factor levels in women with overactive bladder[J]. Gynecol Obstet Invest, 2018, 83(2):140-144.
doi: 10.1159/000477170
|
[10] |
Liu H T, Jiang Y H, Kuo H C. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy[J]. PLoS One, 2013, 8(10):1-5.
|
[11] |
Barker A T, Freeston I L, Jabinous R, et al. Clinical evaluation of conduction time measurements in central motor pathways using magnetic stimulation of human brain[J]. Lancet, 1986, 1(8493):1325-1326.
pmid: 2872449
|
[12] |
Merton P A, Morton H B. Stimulation of the cerebral cortex in the intact human subject[J]. Nature, 1980, 285(5762):227.
pmid: 7374773
|
[13] |
Bemelmans B L, Van Kerrebroeck P E, Notermans S L, et al. Motor evoked potentials from the bladder on magnetic stimulation of the cauda equina: a new technique for investigation of autonomic bladder innervations[J]. J Urol, 1992, 147(3):658-661.
doi: 10.1016/S0022-5347(17)37339-1
|
[14] |
Yamanishi T, Yasuda K, Sakakibara R, et al. Induction of urethral closure and inhibition of bladder contraction by continuous magnetic stimulation[J]. Neurourol Urodyn, 1999, 18(5):505-510.
doi: 10.1002/(ISSN)1520-6777
|
[15] |
Bycroft J A, Craggs M D, Sheriff M, et al. Does magnetic stimulation of sacral nerve roots cause contraction or suppression of the bladder?[J]. Neurourol Urodyn, 2004, 23(3):241-245.
doi: 10.1002/(ISSN)1520-6777
|
[16] |
Khedr E M, Alkady E A, El-Hammady D H, et al. Repetitive lumbosacral nerve magnetic stimulation improves bladder dysfunction due to lumbosacral nerve injury:a pilot randomized controlled study[J]. Neurorehabil Neural Repair, 2011, 25(6):570-576.
doi: 10.1177/1545968311400091
pmid: 21411715
|
[17] |
Takahashi S, Ki tamura T. Overactive bladder: magnetic versus electrical stimulation[J]. Curropin Obstet Gynecol, 2003, 15(5):429-433.
|
[18] |
Nazir J, Kelleher C, Aballéa S, et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis[J]. Neurourol Urodyn, 2018, 37(3):986-996.
doi: 10.1002/nau.v37.3
|
[19] |
Hakimi Z, Kelleher C, Aballéa S, et al. Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK[J]. J Mark Access Health Policy, 2018, 6(1):1-7.
|
[20] |
Tanaka Y, Tanuma Y, Masumori N. Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder[J]. Int J Urol, 2016, 23(10):866-872.
doi: 10.1111/iju.13174
|
[21] |
Kosier J H, Combest W, Newton M. Solifenacin succinate (VESIcare): overactive bladder therapy[J]. Urol Nurs, 2006, 26(6):496-497.
|